Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

Blood (2019) 134 (Supplement_1): 4141.

https://doi.org/10.1182/blood-2019-131113

Published: 2019

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

Mario Scarpa, PhD, Shivani Kapoor, MS, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2018) 132 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2018-99-117609

Published: 2018

Journal Articles

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Blood (2017) 130 (Supplement 1): 45.

https://doi.org/10.1182/blood.V130.Suppl_1.45.45

Published: 2017

Journal Articles

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Justine Yu, B.S., Giovannino Silvestri, PhD, Lorenzo Stramucci, PhD, Masashi Sanada, MD PhD, Tomoyuki Yamaguchi, PhD, Yang Du, PhD, Jukka Westermarck, MD PhD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, Dragana Milojkovic, MD, Jane F. Apperley, MD, Denis-Claude Roy, MD, Guido Marcucci, MD, Bruno Calabretta, MD PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2016) 128 (22): 2909.

https://doi.org/10.1182/blood.V128.22.2909.2909

Published: 2016

Journal Articles

Concurrent Inhibition of Pim-1 and FLT3 Kinases in FLT3-ITD Acute Myeloid Leukemia Post-Translationally Downregulates the Anti-Apoptotic Protein Mcl-1 through Downregulation of the Mcl-1 Deubiquitinase USP9X

Patrick R. Baldwin, PhD, Shivani Kapoor, B.S., Karthika Natarajan, PhD, Rossana Trotta, PhD, Adriana Tron, PhD, Dennis Huszar, PhD, Eduardo Davila, PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2016) 128 (22): 35.

https://doi.org/10.1182/blood.V128.22.35.35

Published: 2016

Journal Articles

Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells

Bin Zhang, PhD, Ling Li, PhD, Ching-Cheng Chen, PhD, Anthony S. Stein, MD, Haris Ali, MD, David S. Snyder, MD, Allen Lin, Adrienne Dorrance, PhD, Piotr Swiderski, PhD, Ravi Bhatia, MD, Danilo Perrotti, MD PhD, Stephen J. Forman, MD, Ya-Huei Kuo, PhD, Marcin Kortylewski, PhD, Guido Marcucci, MD

Blood (2015) 126 (23): 51.

https://doi.org/10.1182/blood.V126.23.51.51

Published: 2015

Journal Articles

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

Blood (2015) 126 (23): 53.

https://doi.org/10.1182/blood.V126.23.53.53

Published: 2015

Journal Articles

The Pim Kinase Inhibitor AZD1208 Enhances Apoptosis Induction By Clinically Active FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and in Vivo through Synergistic Downregulation of Mcl-1 and of Bcl-xL

Karthika Natarajan, PhD, Trevor J Mathias, MS, Kshama A Doshi, MS, Adriana E Tron, PhD, Manfred Kraus, PhD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD, Dennis Huszar, PhD, Maria R Baer, MD

Blood (2014) 124 (21): 3601.

https://doi.org/10.1182/blood.V124.21.3601.3601

Published: 2014

Journal Articles

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Giovannino Silvestri, PhD, Justin Ellis, Lorenzo Stramucci, PhD, Jason G Harb, PhD, Paolo Neviani, PhD, Guido Marcucci, MD, Denis-Claude Roy, MD, Peter Hokland, MD DMSc, Dragana Milojkovic, Alistair Reid, Jane F. Apperley, Ferenc M Livak, PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2014) 124 (21): 4529.

https://doi.org/10.1182/blood.V124.21.4529.4529

Published: 2014

Journal Articles

Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant Aglaia Foveolata inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML)

Houda Alachkar, PharmD, M.S, Ramasamy Santhanam, PhD, David M. Lucas, PhD, Sebastian Schwind, MD, Christopher Hickey, M.S, Jiuxia Pang, Danilo Perrotti, MD, PhD, Li Pan, PhD, A Douglas Kinghorn, Ph.D., D.Sc, Guido Marcucci, MD, Michael R Grever, MD

Blood (2011) 118 (21): 2616.

https://doi.org/10.1182/blood.V118.21.2616.2616

Published: 2011

Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 2901.

https://doi.org/10.1182/blood.V116.21.2901.2901

Published: 2010

Journal Articles

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, S. A Saddoughi, Christopher Walker, Paolo Neviani, Jason G Harb, Y. Ma, Srdan Verstovsek, MD, PhD, Guido Marcucci, MD, Roger Briesewitz, Robert Bittman, Ching-Shih Chen, Alfonso Quintas-Cardama, MD, Besim Ogretmen, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 775.

https://doi.org/10.1182/blood.V116.21.775.775

Published: 2010

Journal Articles

The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia

Nicholas Zorko, Susan P. Whitman, PhD, Kelsie Bernot, PhD, Myntee T. Ngangana, Ronald Siebenaler, Shujun Liu, Ph.D., Yue-Zhong Wu, MS, Chidimma Kalu, Xiaoli Zhang, PhD, MS, David Jarjoura, PhD, Zhiliang Xie, MD, Kenneth K. Chan, PhD, Adrienne M. Dorrance, PhD, Benjamin H. Lee, MD, PhD, Roger Briesewitz, PhD, Danilo Perrotti, MD, PhD, Guido Marcucci, MD, Michael A. Caligiuri, MD

Blood (2010) 116 (21): 150.

https://doi.org/10.1182/blood.V116.21.150.150

Published: 2010

Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Blood (2010) 116 (21): 515.

https://doi.org/10.1182/blood.V116.21.515.515

Published: 2010

Journal Articles

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

Jason G Harb, Paolo Neviani, Joshua J Oaks, Guido Marcucci, MD, Peter Hokland, MD, DMSC, Denis-Claude Roy, MD, FRCPC, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 1222.

https://doi.org/10.1182/blood.V116.21.1222.1222

Published: 2010

Journal Articles

Regulation of Acute Graft-Versus-Host Disease by MicroRNA-155

Nicole Stauffer, Sayed Mehdi Hamadani, MD, Catherine Heaphy, Ramasamy Santhanam, Sukhinder Sandhu, BSc, MSc, Stefan Costinean, Jerry Nuovo, Danilo Perrotti, MD, PhD, Carlo M. Croce, MD, Greg Hadley, Guido Marcucci, MD, Steven M. Devine, MD, Ramiro Garzon, MD

Blood (2010) 116 (21): 245.

https://doi.org/10.1182/blood.V116.21.245.245

Published: 2010

Journal Articles

BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells.

Jason Harb, PhD, Paolo Neviani, PhD, Claudia Huettner, PhD, Guido Marcucci, MD, Danilo Perrotti, MD, PhD

Blood (2009) 114 (22): 191.

https://doi.org/10.1182/blood.V114.22.191.191

Published: 2009

Journal Articles

MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells.

Christopher Hickey, Sebastian Schwind, MD, Heiko Becker, MD, Houda Alachkar, Ramiro Garzon, MD, Yue-Zhong Wu, MS, Shujun Liu, PhD, Danilo Perrotti, MD, PhD, Guido Marcucci, MD

Blood (2009) 114 (22): 766.

https://doi.org/10.1182/blood.V114.22.766.766

Published: 2009

Journal Articles

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

Blood (2009) 114 (22): 855.

https://doi.org/10.1182/blood.V114.22.855.855

Published: 2009

NARROW

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Concurrent Inhibition of Pim-1 and FLT3 Kinases in FLT3-ITD Acute Myeloid Leukemia Post-Translationally Downregulates the Anti-Apoptotic Protein Mcl-1 through Downregulation of the Mcl-1 Deubiquitinase USP9X

Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

The Pim Kinase Inhibitor AZD1208 Enhances Apoptosis Induction By Clinically Active FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and in Vivo through Synergistic Downregulation of Mcl-1 and of Bcl-xL

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant Aglaia Foveolata inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML)

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

Regulation of Acute Graft-Versus-Host Disease by MicroRNA-155

BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells.

MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells.

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only